---
title: "OBiO Tech: Net loss of 105 million yuan in the first half of 2025, a year-on-year narrowing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253423824.md"
description: "OBiO Tech announced that its operating revenue in the first half of 2025 was 120 million yuan, a year-on-year increase of 6.01%. The net loss attributable to shareholders of the listed company was 105 million yuan, compared to a net loss of 113 million yuan in the same period last year"
datetime: "2025-08-18T08:59:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253423824.md)
  - [en](https://longbridge.com/en/news/253423824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253423824.md)
generator: "portal-rs"
---

# OBiO Tech: Net loss of 105 million yuan in the first half of 2025, a year-on-year narrowing

OBiO Tech announced that its operating revenue in the first half of 2025 was 120 million yuan, a year-on-year increase of 6.01%. The net loss attributable to shareholders of the listed company was 105 million yuan, compared to a net loss of 113 million yuan in the same period last year

### Related Stocks

- [688238.CN](https://longbridge.com/en/quote/688238.CN.md)

## Related News & Research

- [Russian forces hit Kyiv petrol station, injuring four](https://longbridge.com/en/news/298565403.md)
- [InnoCare wins China IND clearance to trial PSMA/STEAP1 bispecific ADC ICP-B381](https://longbridge.com/en/news/298389771.md)
- [Shanghai Pharma signs strategic R&D partnership with CAS Shanghai Institute of Materia Medica](https://longbridge.com/en/news/298383149.md)
- [EWG: Double-digit revenue growth and digital platform adoption drive robust margins and returns](https://longbridge.com/en/news/298417346.md)
- [Opus Genetics reports positive Phase 1/2 low-dose Cohort 1 data for OPGx-BEST1 gene therapy in BEST1 retinal disease](https://longbridge.com/en/news/298445913.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**